- Home
- Publications
- Publication Search
- Publication Details
Title
Advances in PSMA-targeted therapy for prostate cancer
Authors
Keywords
-
Journal
PROSTATE CANCER AND PROSTATIC DISEASES
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-28
DOI
10.1038/s41391-021-00394-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The PSMA Targeting Half-Life Extended BiTE® Therapy AMG 160 Has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-Resistant Prostate Cancer
- (2021) Petra Deegen et al. CLINICAL CANCER RESEARCH
- [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
- (2021) Michael S Hofman et al. LANCET
- Vascular-targeted Photodynamic Therapy in Unilateral Low-risk Prostate Cancer in Germany: 2-yr Single-centre Experience in a Real-world Setting Compared with Radical Prostatectomy
- (2021) Luka Flegar et al. European Urology Focus
- Investigating PSMA-targeted radioligand therapy efficacy as a function of cellular PSMA levels and intra-tumoral PSMA heterogeneity
- (2020) Kyle Current et al. CLINICAL CANCER RESEARCH
- Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
- (2020) Silke Gillessen et al. EUROPEAN UROLOGY
- MEDI3726, a prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) in mCRPC after failure of abiraterone or enzalutamide.
- (2020) Johann S. De Bono et al. JOURNAL OF CLINICAL ONCOLOGY
- Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment
- (2020) Aleksei Titov et al. Cancers
- The BiTE (Bispecific T‐Cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types
- (2020) Hermann Einsele et al. CANCER
- Targeted Radionuclide Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives
- (2020) Malwina Czerwińska et al. MOLECULES
- PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
- (2020) Wallace Jones et al. Cancers
- Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate Cancer
- (2020) Isabella Monia Montagner et al. Cells
- 609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)
- (2020) B. Tran et al. ANNALS OF ONCOLOGY
- PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date
- (2020) Emily Nizialek et al. Cancer Management and Research
- Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings
- (2020) Horst-Dieter Hummel et al. Immunotherapy
- Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer
- (2019) Daniel P. Petrylak et al. PROSTATE
- Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis
- (2019) Jianjian Xiang et al. World Journal of Surgical Oncology
- PREDICTORS OF OVERALL AND DISEASE FREE SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS RECEIVING 225Ac-PSMA-617 RADIOLIGAND THERAPY
- (2019) Mike Sathekge et al. JOURNAL OF NUCLEAR MEDICINE
- Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
- (2019) Alec Paschalis et al. EUROPEAN UROLOGY
- Prostate‐specific membrane antigen for the surgical oncologist: interpreting expression beyond the prostate
- (2019) Matthew Farag et al. ANZ JOURNAL OF SURGERY
- 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
- (2019) Fadi Khreish et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 (177Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer
- (2019) John Violet et al. JOURNAL OF NUCLEAR MEDICINE
- Long‐Circulating Prostate‐Specific Membrane Antigen‐Targeted NIR Phototheranostic Agent
- (2019) Marta Overchuk et al. PHOTOCHEMISTRY AND PHOTOBIOLOGY
- PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open‐label single‐arm phase 2 study
- (2019) Daniel P. Petrylak et al. PROSTATE
- Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients
- (2019) Madhav Prasad Yadav et al. CLINICAL NUCLEAR MEDICINE
- Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer
- (2018) Meng Wu et al. DRUG DELIVERY
- 99m Technetium-based Prostate-specific Membrane Antigen–radioguided Surgery in Recurrent Prostate Cancer
- (2018) Tobias Maurer et al. EUROPEAN UROLOGY
- Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2018;73:178–211
- (2018) Silke Gillessen et al. EUROPEAN UROLOGY
- Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
- (2018) Clemens Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
- (2018) Michael S Hofman et al. LANCET ONCOLOGY
- Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication
- (2018) Christopher C. Kloss et al. MOLECULAR THERAPY
- Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-drug Conjugate Targeting PSMA, in Pre-clinical Models of Prostate Cancer
- (2018) Song Cho et al. MOLECULAR CANCER THERAPEUTICS
- TARGETED ALPHA PARTICLE THERAPY FOR NEUROENDOCRINE TUMOURS: THE NEXT GENERATION OF PRRT
- (2018) Ashley Grossman et al. NEUROENDOCRINOLOGY
- Current therapeutic options in metastatic castration-resistant prostate cancer
- (2018) Gianluca Ingrosso et al. SEMINARS IN ONCOLOGY
- New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen
- (2018) Alessia Cimadamore et al. Frontiers in Oncology
- Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
- (2017) Finn Edler von Eyben et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617
- (2017) Hojjat Ahmadzadehfar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-co-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer
- (2017) Meng Wu et al. International Journal of Nanomedicine
- A PSMA-targeted theranostic agent for photodynamic therapy
- (2017) Ying Chen et al. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
- Follow-up of Prostatectomy versus Observation for Early Prostate Cancer
- (2017) Timothy J. Wilt et al. NEW ENGLAND JOURNAL OF MEDICINE
- „PSMA-radioguided surgery“ beim lokalisierten Prostatakarzinomrezidiv
- (2017) T. Horn et al. UROLOGE
- „PSMA-radioguided surgery“ beim lokalisierten Prostatakarzinomrezidiv
- (2017) T. Horn et al. UROLOGE
- A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy
- (2017) Brent A. Williams et al. Oncotarget
- Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer
- (2017) Cordula A. Jilg et al. Theranostics
- Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
- (2017) Congcong Zhang et al. Frontiers in Immunology
- New photosensitizers for photodynamic therapy
- (2016) H. Abrahamse et al. BIOCHEMICAL JOURNAL
- Value of 111 In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up
- (2016) Isabel Rauscher et al. BJU INTERNATIONAL
- Preclinical Evaluation and First Patient Application of 99m Tc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer
- (2016) Stephanie Robu et al. JOURNAL OF NUCLEAR MEDICINE
- 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
- (2016) R. P. Baum et al. JOURNAL OF NUCLEAR MEDICINE
- 225Ac-PSMA-617 for PSMA-Targeted -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen
- (2016) X. Wang et al. MOLECULAR CANCER THERAPEUTICS
- Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response
- (2016) Richard P. Junghans et al. PROSTATE
- PSMA PET and Radionuclide Therapy in Prostate Cancer
- (2016) Kirsten Bouchelouche et al. SEMINARS IN NUCLEAR MEDICINE
- Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer
- (2016) Matthew I. Milowsky et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases
- (2016) Xilin Chen et al. Oncotarget
- Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
- (2016) Hans Klingemann et al. Frontiers in Immunology
- Toxicity and management in CAR T-cell therapy
- (2016) Challice L Bonifant et al. Molecular Therapy-Oncolytics
- Prostate-specific Membrane Antigen–radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer
- (2015) Tobias Maurer et al. EUROPEAN UROLOGY
- Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer
- (2015) Vincent A. DiPippo et al. PROSTATE
- [111In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery
- (2015) Margret Schottelius et al. EJNMMI Research
- Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival
- (2015) Sabrina Genßler et al. OncoImmunology
- An Aptamer–siRNA Chimera Silences the Eukaryotic Elongation Factor 2 Gene and Induces Apoptosis in Cancers Expressing αvβ3 Integrin
- (2015) Ahmad Fawzi Hussain et al. Nucleic Acid Therapeutics
- Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer
- (2014) B. P. Neuman et al. CLINICAL CANCER RESEARCH
- Increased FoxM1 expression is a target for metformin in the suppression of EMT in prostate cancer
- (2014) YIRU WANG et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Current Progress of Aptamer-Based Molecular Imaging
- (2014) A. Z. Wang et al. JOURNAL OF NUCLEAR MEDICINE
- Targeted Prodrug Approaches for Hormone Refractory Prostate Cancer
- (2014) Herve Aloysius et al. MEDICINAL RESEARCH REVIEWS
- Development of Targeted Near-Infrared Imaging Agents for Prostate Cancer
- (2014) X. Wang et al. MOLECULAR CANCER THERAPEUTICS
- Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts
- (2014) Vincent A. DiPippo et al. PROSTATE
- Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer
- (2014) Jose D. Murga et al. PROSTATE
- Development of Tumor-Targeted Near Infrared Probes for Fluorescence Guided Surgery
- (2013) Lindsay E. Kelderhouse et al. BIOCONJUGATE CHEMISTRY
- Treatment of patients with advanced cancer with the natural killer cell line NK-92
- (2013) Torsten Tonn et al. CYTOTHERAPY
- Advanced generation anti-prostate specific membrane antigen designer T Cells for prostate cancer immunotherapy
- (2013) Qiangzhong Ma et al. PROSTATE
- Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
- (2012) M. Friedrich et al. MOLECULAR CANCER THERAPEUTICS
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rational Truncation of an RNA Aptamer to Prostate-Specific Membrane Antigen Using Computational Structural Modeling
- (2011) William M. Rockey et al. Nucleic Acid Therapeutics
- Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption
- (2010) Tiancheng Liu et al. CANCER LETTERS
- Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
- (2010) M.-L. Zhu et al. CANCER RESEARCH
- Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer
- (2009) S. M. Hillier et al. CANCER RESEARCH
- Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors
- (2009) Justin P Dassie et al. NATURE BIOTECHNOLOGY
- In vitro targeted photodynamic therapy with a pyropheophorbide-a conjugated inhibitor of prostate-specific membrane antigen
- (2009) Tiancheng Liu et al. PROSTATE
- Phase I Trial of the Prostate-Specific Membrane Antigen–Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer
- (2008) Matthew D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started